Consistent with these analyses, both the CRM1 inhibitor, verdinexor, and the proteasome inhibitor, bortezomib, showed dose-dependent inhibition of 143B and 17-3X human osteosarcomas (Figure 4I,J) and D418 and D17 canine osteosarcomas (Figure 4K,L), pinpointing the CRM1 and proteasome pathways as lead candidates for in vivo validation. The gene discussed is XPO1; the disease is osteosarcoma.